AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction

RecruitingNAAges 18 Years - 80 YearsAllEfferon JSC
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction. Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop. The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (โ‰ค55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction * Stages B - C of cardiogenic shock according to SCAI * Patient condition allows treatment with Efferonยฎ CT device for at least 4 hours * SOFA score 12 or less Exclusion Criteria: * Broken-heart syndrome (takotsubo cardiomyopathy) * Postcardiotomy cardiogenic shock * Acute myocardial infarction within the last 4 weeks * Myocarditis * Cardiac trauma * Charlson comorbidity index greater than 9 points * Chronic kidney disease, stage 5 D (requiring continuous hemodialysis) * Acute pulmonary embolism * Acute cerebral circulatory collapse * Transfusion reaction * Patients on immunosuppressive therapy for cancer and autoimmune diseases * Pregnancy * Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study
๐Ÿ’Š

What it tests

  • Efferon CT
๐Ÿ“

Where

1 site
Tomsk NRMC Cardiology Research Institute
Tomsk, Russia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy